Creyon: Creyon Bio secures second patent for AI-powered oligonucleotide engineering
Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent.
Read full article »
Creyon is a California-based preclinical stage company that researches and commercializes oligonucleotide medicines for the treatment of respiratory diseases.
Read more